H.C. Wainwright Bullish on AtaiBeckley (ATAI)

AtaiBeckley Inc. (NASDAQ:ATAI) earns a place on our list of the top 10 stocks under $5 that could triple.

H.C. Wainwright Bullish on AtaiBeckley (ATAI) Following Phase 2a Data for BPL-003

A closeup of a laboratory assistant, holding up a vial of a newly developed pharmaceutical product.

Analysts are strongly supportive of AtaiBeckley Inc. (NASDAQ:ATAI) amid recent clinical updates.

H.C. Wainwright reaffirmed its “Buy” rating and $25.00 price target on March 17, 2026, indicating significant upside from the current $3.65 level.

The recent Phase 2a data for BPL-003 bolstered confidence in AtaiBeckley Inc. (NASDAQ:ATAI)’s pipeline. The findings reinforced the company’s position in the 5-MeO-DMT class by demonstrating that a single dose produces a therapeutic effect that intensifies over time and lasts for at least 12 weeks.

The data, which highlights rising confidence in AtaiBeckley Inc. (NASDAQ:ATAI)’s clinical differentiation of the asset, was cited by the firm as a strong signal that continues to set the benchmark for the class.

AtaiBeckley Inc. (NASDAQ:ATAI), following an end-of-Phase 2 meeting, reached an agreement with the FDA on the dual-trial design for its planned Phase 3 program. This milestone supports the overall momentum and keeps the program on schedule for launch in Q2 2026. Prior to this, BPL-003 was designated as a Breakthrough Therapy in October 2025.

Srinivas Rao, Co-Founder and CEO, stated,

“BPL-003 has demonstrated rapid, durable antidepressant effects, and the FDA’s supportive End-of-Phase 2 feedback enables us to advance into two parallel Phase 3 trials beginning in Q2 2026. With Breakthrough Therapy Designation and a robust pivotal design, we believe BPL‑003 has the potential to meaningfully reshape the treatment landscape for TRD.”

AtaiBeckley Inc. (NASDAQ:ATAI), a clinical-stage biopharmaceutical company, focuses on developing effective, rapid-acting, and convenient mental health treatments.

While we acknowledge the risk and potential of ATAI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ATAI and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.